Targets › CSNK1E
4 programs from 4 companies in 4 trials: 3 Phase 2, 1 Phase 1; Oncology; next expected readout Jan 2027.
Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates (Probable). Participates in Wnt signaling. (UniProt, P49674)
Open in Phaseline: the race on CSNK1E, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Umbralisib PI3-kinase p110-delta subunit inhibitor; Casein kinase I epsilon inhibitor; Tyrosine-protein kinase ABL inhibitor | PIK3CD, CSNK1E, ABL1 | Phase 2 | Grade 1 Follicular Lymphoma | Jan 2027 |
| City of Hope Medical Center | Umbralisib PI3-kinase p110-delta subunit inhibitor; Casein kinase I epsilon inhibitor; Tyrosine-protein kinase ABL inhibitor | PIK3CD, CSNK1E, ABL1 | Phase 2 | Mantle Cell Lymphoma | Jul 2027 |
| Jennifer R. Brown, MD, PhD | Umbralisib PI3-kinase p110-delta subunit inhibitor; Casein kinase I epsilon inhibitor; Tyrosine-protein kinase ABL inhibitor | PIK3CD, CSNK1E, ABL1 | Phase 2 | Chronic Lymphocytic Leukemia | Jan 2028 |
| University of Chicago | Umbralisib (TGR-1202) PI3-kinase p110-delta subunit inhibitor; Casein kinase I epsilon inhibitor; Tyrosine-protein kinase ABL inhibitor | PIK3CD, CSNK1E, ABL1 | Phase 1 | CLL | Dec 2027 |
Mantle Cell Lymphoma (1) Chronic Lymphocytic Leukemia (1) Grade 1 Follicular Lymphoma (1) CLL (1)
mixed (4)
City of Hope Medical Center (1) Jennifer R. Brown, MD, PhD (1) National Cancer Institute (NCI) (1) University of Chicago (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.